Proteomics International Laboratories managing director Dr Richard Lipscombe said: “This new Australian study reinforces the growing body of evidence demonstrating that PromarkerD provides actionable information that can meaningfully change how clinicians manage patients with type 2 diabetes.”
Moderate-risk patients also saw notable treatment adjustments, with clinicians optimising dosages or reducing exposure to drugs that are potentially harmful to the kidneys.
High-risk PromarkerD scores also led to more frequent monitoring, every 3–6 months, coupled with specialist referrals, while lower-risk scores correspondingly reduced the need for patient monitoring.
Senior author Professor Merlin Thomas, a nephrologist and Professor of Medicine at Monash University in Melbourne, said that PromarkerD provides an opportunity to identify those at risk of chronic kidney disease much earlier, before clinical signs of decline are evident.
He added that when clinicians were shown moderate or high-risk PromarkerD results, they were far more likely to initiate kidney-protecting therapies and increase monitoring frequency. They also became more cautious about using medications that can harm the kidneys, such as ibuprofen, compared with cases where they did not have the PromarkerD results.
He explained that these changes can also help prevent or delay progression to kidney failure and reduce the need for interventions such as dialysis or a kidney transplant.
Notably, 89 per cent of physicians believed PromarkerD would improve clinical outcomes, with over 85 per cent viewing it as helpful in guiding decisions and potentially reducing healthcare costs.
The company says the results mirror previously reported positive findings in the US. They also underscore PromarkerD’s role in addressing an unmet need for the early detection of diabetes-related kidney disease in Australia’s 1.5 million adults with the condition.
As diagnostic tools such as PromarkerD advance, they offer renewed hope for better management of diabetes and kidney disease risks across all populations, enabling earlier interventions and improved long-term outcomes for millions worldwide.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
